Voyager Therapeutics shares soar after Novartis $1.2 billion deal

CAMBRIDGE, Mass. – Shares of Voyager Therapeutics surged after announcing a strategic partnership with pharmaceutical giant Novartis. The collaboration, which focuses on developing candidate gene therapies for Huntington’s disease, is expected to generate milestone payments of up to $1.2 billion for Voyager.

The agreement gives Novartis exclusive rights to Voyager’s proprietary TRACER capsid screening platform. This technology is expected to play a key role in the development of gene therapy candidates. As part of the deal, Voyager received a substantial upfront payment of $100 million.

Investors reacted positively to the news, with Voyager shares soaring to the $10 mark today. This partnership not only provides Voyager with direct financial benefits, but the company can also receive tiered royalties on future sales if the gene therapy candidate is successful in the market.

This article was created and translated with the help of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.